Ceribell, Inc., a Mountain View, CA-based provider of a Rapid Response EEG System to improve the diagnosis and treatment of patients at risk for seizures, completed a $35m Series B financing.
The round was led by new investors Optimas Capital Partners Fund and The Rise Fund, with participation by UCB and LivaNova.
The company intends to use the funds to expand commercialization of its system.
Led by Jane Chao, Ph.D., CEO, Ceribell has developed a technology platform designed to address the need for faster diagnosis of patients with suspicion of seizure to enable clinicians to make appropriate treatment decisions.
The Ceribell EEG System consists of a disposable headband and a mobile recorder that acquires and transmits data to a HIPAA compliant cloud portal for a specialist to review the patient’s EEG from anywhere. The system, which can be set up in minutes by any healthcare provider, allows for bedside triage by the treating physician by using the proprietary Brain Stethoscope feature which converts EEG signals to sound.
The Ceribell EEG System received FDA 510(k) clearance in 2017 and is commercially available in the United States.